---
sidebar_position: 73
---
           <p class="stitle-article-norm">Clinical investigations regarding devices bearing the CE marking</p>
   <p class="norm">1.&nbsp;&nbsp;Where a clinical investigation is to be
 conducted to further assess, within the scope of its intended purpose, a
 device which already bears the CE marking in accordance with 
Article&nbsp;20(1), (‘PMCF investigation’), and where the investigation 
would involve submitting subjects to procedures additional to those 
performed under the normal conditions of use of the device and those 
additional procedures are invasive or burdensome, the sponsor shall 
notify the Member&nbsp;States concerned at least 30 days prior to its 
commencement by means of the electronic system referred to in 
Article&nbsp;73. The sponsor shall include the documentation referred to
 in Chapter II of Annex&nbsp;XV as part of the notification. Points (b) 
to (k) and (m) <span>
         <a href="https://eur-lex.europa.eu/legal-content/EN/AUTO/?uri=celex:32017R0745R%2801%29" onclick="window.open(this.href,'_blanc'); return false;" title="32017R0745R(01): REPLACED">
            <span class="boldface">►C1</span>
         </a><a class="anchorarrow" id="C1-4" href="#C1-5"><i class="fa fa-arrow-down" title="NEXT" ></i></a>
      </span>&nbsp;of Article 62(4), Articles 75, 76 and 77, and Article 80(5) and (6), and the relevant provisions<span class="boldface">&nbsp;◄ </span> of Annex&nbsp;XV shall apply to PMCF&nbsp;investigations.</p>
   <p class="norm">2.&nbsp;&nbsp;Where a clinical investigation is to be
 conducted to assess, outside the scope of its intended purpose, a 
device which already bears the CE marking in accordance with 
Article&nbsp;20(1), Articles&nbsp;62 to 81 shall apply.</p>